Joanna Van Elk

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A. Sallman, Adam S. Asch, Monzr M. Al Malki et al. · Blood · 2019 · 220 citations

Medicine, Immunology, Pharmacology +11

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

David A. Sallman, Monzr Al Malki, Adam S. Asch et al. · Journal of Clinical Oncology · 2020 · 82 citations

Medicine, Immunology, Pharmacology +17

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

David A. Sallman, William B. Donnellan, Adam S. Asch et al. · Journal of Clinical Oncology · 2019 · 65 citations

Medicine, Oncology, Pharmacology +17

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

David A. Sallman, Adam Asch, Suman Kambhampati et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 51 citations

Medicine, Oncology, Pharmacology +10

Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection

Raphael B. Stricker, Yu Sheng Zhu, Blaine F. Elswood et al. · Immunology Letters · 1993 · 34 citations

Life Sciences, Infectious Diseases, Pharmacology +6